Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7061 USD | +3.84% | 0.00% | -91.13% |
Apr. 11 | US Equity Markets Close Mixed After March Producer Price Inflation Data | MT |
Apr. 11 | Top Midday Decliners | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 29.64 | 160.5 | 38.55 | 11.81 | 3.41 | 1.135 | - | - |
Enterprise Value (EV) 1 | 29.64 | 160.5 | 38.55 | 11.81 | 3.41 | 1.135 | 1.135 | 1.135 |
P/E ratio | -0.66 x | -7.01 x | -1.3 x | 1.48 x | -0.13 x | -0.03 x | -0.09 x | -0.16 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 0.91 x | 37.2 x | 3.14 x | 3.79 x | - | - | - | 0.12 x |
EV / Revenue | 0.91 x | 37.2 x | 3.14 x | 3.79 x | - | - | - | 0.12 x |
EV / EBITDA | - | - | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 73.5 | 99.5 | 111 | 116 | 428 | 1,607 | - | - |
Reference price 2 | 403.2 | 1,613 | 346.3 | 102.1 | 7.964 | 0.7061 | 0.7061 | 0.7061 |
Announcement Date | 3/25/20 | 3/31/21 | 3/24/22 | 3/30/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 32.42 | 4.309 | 12.29 | 3.114 | - | - | - | 9.43 |
EBITDA | - | - | - | - | - | - | - | - |
EBIT 1 | -42.6 | -27.49 | -21.4 | -28.64 | -28.88 | -25.68 | -27.17 | -20.08 |
Operating Margin | -131.37% | -638.06% | -174.1% | -919.75% | - | - | - | -212.88% |
Earnings before Tax (EBT) 1 | -44.7 | -30.92 | -29.41 | 7.014 | -18.65 | -25.85 | -28.87 | -10.48 |
Net income 1 | -40.45 | -17.75 | -28.46 | 8.027 | -17.41 | -25.68 | -27.17 | -20.08 |
Net margin | -124.75% | -411.93% | -231.51% | 257.77% | - | - | - | -212.88% |
EPS 2 | -609.8 | -230.1 | -267.1 | 69.08 | -62.48 | -20.18 | -8.075 | -4.475 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/25/20 | 3/31/21 | 3/24/22 | 3/30/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 3.096 | 3.665 | 3.114 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -4.75 | -4.04 | -5.611 | -7.562 | -7.784 | -7.684 | -7.756 | -8.178 | -6.561 | -6.384 | -6.415 | -6.447 | -6.479 | -6.512 |
Operating Margin | -153.42% | -110.23% | -180.19% | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.997 | -6.597 | -7.875 | 27.86 | -7.809 | -5.163 | 1.827 | -7.948 | -6.334 | -6.196 | -6.415 | -6.447 | -6.479 | -6.512 |
Net income 1 | -6.997 | -6.272 | -7.697 | 28.01 | -7.644 | -4.642 | 2.773 | -7.948 | -6.334 | -5.903 | -6.415 | -6.447 | -6.479 | -6.512 |
Net margin | -226% | -171.13% | -247.17% | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -62.92 | -55.88 | -68.20 | 245.5 | -66.00 | -41.80 | 17.16 | -54.12 | -22.00 | -6.160 | -12.84 | -6.530 | -3.900 | -3.840 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/21 | 3/24/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/30/23 | 5/11/23 | 8/10/23 | 11/14/23 | 3/5/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/25/20 | 3/31/21 | 3/24/22 | 3/30/23 | 3/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-91.13% | 1.13M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.05% | 22.15B | |
-17.37% | 21.02B | |
-8.31% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- APVO Stock
- Financials Aptevo Therapeutics Inc.